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W0~ Cyclopenta-fused polycyclic aromatic
.ac .y.w.a.b. hydrocarbons (CP-PAHs) are an important
class of PAH that is abundant in the efflu-
ent from a number of different combustion
systems and is also present in airborne par-
tiuaematter (1-14). A growing body of
data has revealed that many CP-PAHs are
mutagens and animal carcinogens and thus
~do~ potentially pose a significant health threat
to humans (2,9-22).
CPAA and PA?is dscebed. Thea&t ...t Using a combination of analytical tech-
nqe,we have identified severalCH ~~18 10
CP-PAHs in products from different com-
bustors and pyrolyzers operated over a
of conditions (4 -6). Of the
several C 18H isomers possibly present,
Cii~~j:~ cyclopenta[calpyrene (CPP) was found in
an earlier study to be the most important
bacterial mutagen emitted from a jet-
stirred/plug-flow reactor (5). In addition
to CPP, one of the other C 18H PAHs
found in the sample was postulated to be
benzo[ghu]fluoranthene (BF); however, the
lack of reference standards pr v n e
~ unequivocal identification.
To identify other C18H isomers and
to determine their contribution to the
overall mutagenicity of combustion and
pyrolysis samples, we characterized refer-
ence samples of four C 18H PAHs cyclo-
~ pent[hz]acephenanthrylene (CPAP), CPP,
cyclopent[hi]aceanthrylene (CPAA), and
aeat-~ BF. In addition, we compared the bacteri-
al and human cell mutagenicity of CPAA
and CPAP with those of their monocy-
clo enta-fused analogs, aceanthrylene (AA)
esrlOl146..I5(1~93)and acephenanthrylene (AP), to determine
the effect of adding an additional fused
cyclo-penta group. All PAHs were pro-
duced synthetically, except for BF, which
was obtained commercially. Structures
and nomenclature are shown in Figure 1.
We identified 1C10 isomers in com-
bustion samples by GC/MS and HPLC
with diode-array spectrophotometric detec-
tion. Results are presented for fuel-rich
ethylene combustion products from a jet-
stirred/plug-flow reactor. The four C H
PAH isomers were tested for mutagenicity
in a forward mutation assay based on
Salmonella typhimurium. They were also
tested for mutagenic activity in human
cells.
Methods
The jet-stirred/plug-flow combustor was
designed to provide well-defined combus-
tion conditions, and its use is part of an
ongoing program aimed at understanding
and controlling the combustion chem-
istry responsible for mutagen formation.
Fuel-rich combustion in a jet-stirred
reactor (fuel equivalence ratio, 2.37,
C/O, 0.791) provides baseline input to a
close-coupled, plug-flow reactor where
continuing molecular-weight growth
reactions occur. Detailed descriptions of
this combustor are available elsewhere
(23-25).
In this study, the fuel was ethylene
(fuel equivalence ratio, 2.37; residence
time, 5.69 msec; reactor temperature,
16280K). We obtained samples from the
plug-flow region of the combustor using
an aspirated probe connected to a high-
yield combustion sampler consisting of
two refrigerated traps containing a total
of 4 1 of dichloromethane. The first trap
was maintained at -30'C and the second
at -680C. Samples were concentrated in
a 1-1 Kuderna-Danish evaporative con-
centrator to the dissolution limit and fil-
tered through a 0.2-Jim fluorocarbon fil-
ter to remove particulates.
The HPLC system used for chemical
analysis consisted of a Hewlett-Packard
Model 1090 ternary gradient pumping
system with 190-600-nm diode-array
detector. It used HPLC operating soft-
ware running on a Model 7994 Analyti-
cal Work-station. Injection volumes
ranging from 1 to 25 W. could be select-
ed. The HPLC column was a Vydac
201TP C18 type optimized for PAH sep-
arations (Vydac, Inc., Hesperia, CA;
diameter, 4.6 mm; length 250 mm). The
column was packed with 5 gim material
of300 A pore size.
The mobile phase consisted of acetoni-
trile and water. The solvent program con-
sisted of a linear ramp from 40% acetoni-
trile/60% water to 100% acetonitrile in 80
min. The flow rate was 1.0 ml! min UV-
visible spectra (200-600 nm) were ob-
tained at 0.10-sec intervals. Total absor-
bance chromatograms shown in this work
were recorded over the 236-500 nm wave-
length interval. The use of wideband
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Figure 1. Structure and nomenclature of C16H1o and C18H10 cyclopenta-fused polycyclic aromatic hydro-
carbons studied.
diode-array detection for the analysis of
polycyclic aromatic compounds has been
reported elsewhere (26).
GC/MS consisted of an HP 5890 gas
chromatograph connected to a model 5970
mass selective detector. Data acquisition
and analysis were accomplished using a
model 59970C MS ChemStation. The
instrument was obtained from Hewlett-
Packard (Palo Alto, CA). The GC column
was a methyl-(5%-phenyl)silicone FSOT
column (Quadrex, Inc.) with a length of
25 m, an i.d. of 0.25 mm, and a film
thickness of 0.25 pim. Column tempera-
ture programming was from 40°C to
280°C at 10°C/min. Injector and transfer
lines were at 280°C. Injection volume was
1.0 gl. HPLC solvents were Caledon
HPLC grade obtained from American
Bioanalytical (Natick, MA). BF was ob-
tained from the Bureau of Community
Reference (Brussels). AA, AP, CPP,
CPAA, and CPAP were produced syntheti-
cally.
Mutagenicity Assays
The samples, dissolved in dichlorometh-
ane, were prepared for bioassay by adding a
measured amount ofdimethyl sulfoxide in
a V-bottom vial. We evaporated the
dichloromethane with a gentle stream of
nitrogen until the total volume was re-
duced to that of the original dimethyl sul-
foxide. Sample concentrations in dimethyl
sulfoxide were typically 10-20 mg/ml.
We used the forward mutation assay to
8-azaguanine resistance in S. typhimurium
strain TM677 to measure bacterial muta-
genicity. Detailed protocols for measuring
forward mutation have been described pre-
viously (27-29). Briefly, we suspended
exponentially growing bacteria in medium
in the presence of test sample for 2 hr.
Samples at a number of concentrations
ranging from 0.10 to 20 pg/ml, depending
on their mutagenic potency, were exposed
to the bacteria in the presence of 5% (v/v)
Aroclor-induced post-mitochondrial super-
natant (PMS). Cultures containing PMS
had an NADPH-generating system. After
2 hr we resuspended cells in fresh medium.
Aliquots were plated in the presence or
absence of the selective agent (8-azagua-
nine, 50 pg/ml). We performed each assay
in duplicate with triplicate plates for each
experiment.
We counted colonies at 48 hr and
determined the mutant fraction (MF) as
the number of colonies formed under
selective conditions divided by the number
ofcolonies formed under nonselective con-
ditions multiplied by the dilution factor.
The assay was ruled positive ifat any sam-
ple concentration: 1) the number of mu-
tant colonies in the treated cultures was
greater than the number of mutant col-
onies in the control cultures with greater
than 99% confidence as calculated by
Poisson distribution, and 2) the MF
exceeded the 95% upper confidence limit
for the cumulative historical control (14 x
10o-5).
We tested compounds for mutagenic
activity at the thymidine kinase (tk) locus in
MCL-3 cells. These cells were derived from
an L3 variant (30) ofAHH-1 TK+/- cells, a
metabolically competent line of human B-
lymphoblastoid cells containing cytochrome
CYPlA1 (31). MCL-3 cells were derived
from L3 cells by transfection ofthe plasmid
pME23, which contains cDNAs for human
cytochromes CYP1A2 and CYP2A6 and
microsomal epoxide hydrolase (32). L3
cells have a 2-fold higher CYPlAI activity
and a lower background mutation frequen-
cyat the tklocus than AHH-1 cells.
We adapted the assay protocol from
the procedure used with AHH-1 cells
(33). Exponentially growing cells were
incubated in duplicate cultures (6 x 106
cells per 12-ml culture) containing differ-
ent concentrations of test compound for
28 hr. We terminated this treatment
phase by centrifuging the cells and resus-
pending them in 50 ml fresh media. One
day later we counted the cells and added
sufficient fresh media to reduce the cell
concentration to 2 x 105 cells/ml. The
cells were grown for an additional 2 days
without further dilution to allow for phe-
notypic expression of the mutants.
Finally, we plated the cells from each
experiment in duplicate 96-well micro-
titer plates in both the presence and
absence of 4.0 g/ml trifluorothymidine as
the selective agent to measure mutagenici-
ty and plating efficiency, respectively. For
the mutagenicity measurements 20,000
cells/well were plated; for measurements of
plating efficiency, 2 cells/well were plated.
We incubated the plates for 13 days and
scored them for the presence of a colony
in each well. The positive control was 5
g/ml benzo[a]pyrene, and the negative
control was 60 p1 of the solvent vehicle
(dimethyl sulfoxide).
We pooled the plate counts for each
replicate culture and calculated the MF
according to the Poisson distribution (34).
For a mutagenic response to be considered
significant, the mean MF must be greater
than the 95% confidence limit ofthe con-
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147current negative control (Dunnet's t test)
and must be greater than the 99% upper
confidence limit of the historical control
observations (35). We estimated toxicity
by cumulative growth of the cell cultures
from the beginning oftreatment to plating.
Relative survival was calculated by dividing
the cumulative growth ofthe sample-treat-
ed cultures by the cumulative growth ofthe
negative control cultures.
Synthesis
(In this section, boldface numbers refer to
the corresponding compounds in Figure
2.) CPP was prepared from pyrene accord-
ing to the method published in the litera-
ture (36). AA and CPAA were both pre-
pared from anthracene by methods we
have described (37,38). For the synthesis
of AP (Fig. 2), we treated phenanthrene
with formaldehyde and hydrochloric acid
(36). This gave a mixture of 1-(chloro-
methyl)phenanthrene (1) and 9-(chloro-
methyl)phenanthrene (2) (ratio 1:6). This
mixture was treated under phase transfer
catalytic conditions with sodium cyanide
yielding a mixture of 1-(phenanthrene)ace-
tonitrile (3) and 9-(phenanthrene)acetoni-
trile (4). Saponification with KOH in
refluxing ethanol afforded the correspond-
ing acetic acid derivatives (5 and 6).
Conversion of the acids to their corre-
sponding acid chlorides with oxalyl chlo-
ride (37) and subsequent treatment with
AlCl3 yielded a mixture of acephenan-
thren-4-one (7) and acephenanthren-5-one
(8). NaBH4 reduction ofthe ketones and
subsequent dehydration with p-tol-uene
sulfonic acid gave AP as yellow plates in
25% overall yield starting from phenan-
threne.
For the preparation of CPAP (Fig. 2),
we reduced the mixture of 7 and 8 under
Wolff-Kishner conditions to yield ace-
phenanthrene (9). Acephenanthrene was
treated with oxalyl chloride with AICl3 as
catalyst. In this way the second five-mem-
bered ring was introduced, forming 6,7-
dihydrocyclopent[h:iacephenanthrene-4,5-
dione (10). Wolff-Kishner reduction
afforded 4,5,6,7-tetrahydrocyclo-
pent[hi]acephenanthrylene (11). Treat-
ment ofcompound 11 with 2,3-dicholoro-
5,6-dicyano-1,4-benzoquinone (DDQ) in
toluene led to the fully conjugated CPAP as
dark-yellowplates.
All reagents were commercially available
and were used without further purification.
Solvents were distilled before use and dried
ifnecessary. Petroleum ether with a boiling
range of 60-80°C was used. Silica gel
(230-400 mesh) was supplied by Merck.
Melting points were determined on a
Pleuger-Buchi melting point apparatus and
are uncorrected; 300 MHz 1H-NMR spec-
tra were recorded on a Bruker WM-300
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Figure 2. Synthesis of acephenanthrylene (scheme 1) and cyclopent[hulacephenanthrylene (scheme 2).
For a discussion of intermediates, see text.
spectrometer with CDC13 as solvent, unless
stated otherwise. We used tetramethylsi-
lane (d = 0) as an internal standard. Chem-
ical shifts (d) are given in ppm and cou-
pling constants (D) in hertz. UV-visible
spectra were determined on a Varian DMS
200 spectrophotometer. The mass spectra
were determined on a Varian MAT 711
mass spectrometer (70 eV, source tempera-
ture 150°C, inlet temperature as reported).
1-(Chloromethyl)phenanthrene (1) and
9-(Chloromethyl)phenanthrene (2). Phen-
anthrene was chloromethylated according
to the procedure of Fernandez et al. (39).
After work-up we purified the crude prod-
uct by flash chromatography over a short
column ofsilica. This procedure was suffi-
cient to remove slow-running degradation
components and to obtain the reaction
products sufficiently pure for the next reac-
tion step. IH-NMR revealed, next to 9-
(chloromethyl)phenanthrene (2), some 1-
(chloromethyl)phenanthrene (1) in the
reaction mixture (ratio of 1 and 2, 1:6).
The total yield ofcompounds 1 and 2 was
95%. Compound 2: 1H-NMR: d 5.11 [s,
2H, -CH2Cl]; 7.58-7.75 [m, 4H, H(2,
3,6,7)]; 7.82 [s, H(10)]; 7.88 [m, H(8)];
8.22 [m, 2H, H(4,5)].
1-(Phenanthrene)acetonitrile (3)and9-
(Phenanthrene)acetonitrile (4). A mixture
of 1 and 2 (21.7 g, 95 mmol), NaCN (7.5
g, 153 mmol) and triethylbenzylammoni-
um chloride (3.2 g, 14.5 mmol) was sus-
pended in a mixture of CH2Cl2 (30 ml)
and H20 (6 ml) under stirring. The sus-
pension was refluxed for 16 hr and then
allowed to cool to room temperature. We
added a 5% NaOH solution and extracted
the reaction mixture with CH2Cl2. We
washed the organic layer twice with water
and dried it over MgSO4. An equal
amount ofpetroleum ether was added, and
the solution was filtered over a short col-
umn of silica and Hyflo to remove slow-
running degradation products. Evapor-
ation of the solvent yielded a mixture of
compounds 3 and 4 (ratio 1:6; 18.7 g,
91%) as a light-brown oil. Compound 4:
IH-NMR: d 4.20 [s, 2H, CH2CN] 7.61-
7.77 [m, 5H, H(2,3,6,7,9)]; 7.89-7.93 [m,
2H, H(1,8)]; 8.67-8.79 [m, 2H, H(4,5)].
In the NMR spectrum the 1-isomer (3) is
discernible by a singlet of the CH2CN
group at 4.27 ppm.
J-(Phenanthryl)acetic acid (5) and 9-
(Phenanthryl)acetic acid (6). A mixture of
compounds 3 and 4 (18.0 g, 83 mmol) was
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dissolved in a mixture of ethanol (125 ml)
and water (20 ml) under stirring. We
added KOH (23.5 g) and refluxed the reac-
tion mixture for 24 hr. The solution was
allowed to cool to room temperature and
water was added. We extracted the basic
layer twice with diethyl ether to remove
unreacted products and a small amount of
residual phenanthrene. The basic layer was
acidified with concentrated HCl and ex-
tracted twice with diethyl ether. The com-
bined organic layers were dried overMgSO4
and the solvent was evaporated. Com-
pounds 5 and 6 (ratio 1:6) were isolated as a
white powder (14.7 g, 76%). Compound
6: 1H-NMR: d 4.17 [d,J 1.5, 2H H(a,a')];
7.57-7.71 [m, 4H, H(2,3,6,7)]; 7.72 [s,
H(10)]; 7.87 and 8.03 [2m, H(1 and 8)];
8.67 and 8.75 [2m, H(4 and 5)]. MS
(1250C) m/z (%): 236 (72), 222, (47), 205
(11), 191 (100), 189 (28), 177 (16), 176
(13), 165 (18). In the NMR spectrum the
1-isomer (5) is discernible by asinglet ofthe
CH2COOH group at 3.92 ppm.
Acephenanthren-4-one (7)andAcephen-
anthren-5-one (8). A mixture of crude
compounds 5 and 6 (12.5 g, 53 mmol) was
cyclized according to the procedure ofAmin
et al. (40). After work-up and column
chromatography (silica; CH2CI2/ petroleum
ether 3:1), 5.0 g (44%) ofayellow mass was
obtained, consisting ofcompounds 7 and 8
in a ratio of4:1. Compound 7: 1H-NMR:
d 3.72 [s, 2H, H(5,5')]; 7.56 [s, H(6)]; 7.63
[m, 2H, H(8,9)]; 7.77 [dd,J8.0, 7.3 H(2)];
7.87 [m, H(7)]; 7.98 [d, J7.3 H(3)]; 8.53
[m, H(10)); 8.63 [d, J8.0, H(1)]. Com-
pound 8: H-NMR: d 3.85 [s, 2H, H(4,
4')]; 7.56 [d, J7.1, H(3)]; 7.67 [m, H(9)];
7.72 [dd,J8.4, 7.1, H(2)]; 7.79 [m, H(8)];
8.09 [d, J8.0, H(7)]; 8.21 [s, H(6)]; 8.42
[d,J8.4, H((1)]; 8.65 [d,J8.3, H(10)].
Acephenanthrylene. A mixture ofcom-
pounds 7 and 8 (270 mg, 1.2 mmol) was
dissolved in a mixture of CH2Cl2 (25 ml)
and CH30H (25 ml). We added NaBH4
(230 mg, 6 mmol) to the stirred solution.
Stirring was continued for 30 min. Water
was added, and the mixture was extracted
with CH2Cl2. We dried the organic layer
over MgSO4 and evaporated it to dryness.
The crude mixture ofalcohols was dissolved
in dry toluene (50 ml), and a catalytic
amount ofp-toluene sulfonic acid (15 mg)
was added. The solution was refluxed for
30 min and allowed to cool to room tem-
perature. We then washed the solution
with a saturated NaHCO3 solution and
water and dried it over MgSO4. The sol-
vent was evaporated under reduced pres-
sure. Column chromatography (silica;
CH2Cl2/petroleum ether 1:9) and recrystal-
lization (methanol) gave AP (215 mg, 86%)
as yellow plates, melting point 140-1410C
[literature values 140-141°C; (40) 141-
1420C (41)]. AP: 1H-NMR: d 7.10 [d, J
5.3, H(S)]; 7.20 [d, J 5.3 H(4)]; 7.60 [m
H(8)]; 7.63-7.72 [m, 3H, H(2, 3,9)]; 7.99
[s, H(6)]; 8.00 [d, J7.9, H(7)]; 8.39 [dd, J
7.6, 1.8, H(1)]; 8.64 [d,J8.1, H (10)]. UV
(cyclohexane) [Xmax' nm; (E, 1-molE cm-1)]:
233 (27600), 264 (28800), 288 (9200),
300 (10400), 317 (6200), 330 (6750), 347
(6800), 365 (7900). Exact mass calculated
for C16H10: 202.0782 m/z, found
202.0781 m/z, MS (25°C) m/z (%): 202
(100), 201 (13), 200 (17), 101 (19).
Acephenanthrene (9). A mixture of
compounds 7 and 8 (5.0 g, 22.9 mmol) was
suspended in diethylene glycol (150 ml)
under an argon atmosphere. Hydrazine
monohydrate (15 ml, 190 mmol) was
added, and the reactants were dissolved
under slight heating. After 1 hr we distilled
off excess water and hydrazine until the
temperature of the reaction mixture re-
ached 160°C. We allowed the solution to
cool to 80°C and added KOH (15 g) in
portions. The solution was refluxed for 3 hr
and finally cooled to room temperature.
Water (150 ml) was added, and the reaction
mixture was extracted with diethyl ether
(2X). The combined organic layers were
washed with water (2X) and dried over
MgSO4. Evaporation of the solvent gave
the crude compound 9. Purification by
means of column chromatography (silica;
CH2Cl2/petroleum ether 1:9) yielded
acephenanthrene (4.05 g, 87%) as white
plates, melting point 106-106.5°C [litera-
ture value 106°C (42)]. Compound 9: 1H-
NMR: d 3.45 [s, 4H, H(4,4', 5,5')]; 7.46
[d, J 7.0, H(3)]; 7.52 [s, H(6)]; 7.57 [m,
2H, H(8,9)]; 7.62 [dd, J 8.1, 7.0, H(2)];
7.85 [m, H(7)]; 8.31 [d,J8.1, H(1)]; 8.59
[m, H(10)]. UV (cyclohexane), [max' nm;
(relative £)]: 258 (1.00) 280 (0.18), 292
(0.17), 304 (0.22), 321 (0.011), 336
(0.022), 347 (0.009), 353 (0.028). MS
(250C) m/z (%): 204 (100), 203 (54), 202
(41), 201 (15), 200 (9), 101 (26).
6,7-Dihydrocyclopent[hi]acephenan-
thrylene-4,5-dione (10). Acephenanthrene
(3.3 g. 16.2 mmol) was dissolved in CS2
(50 ml). We added aluminum chloride (5.3
g, 40.3 mmol) and oxalyl chloride (3.1 g,
24.4 mmol) at 0°C under an atmosphere of
argon. Stirring was continued for 5 hr at
0°C and for 16 hr at room temperature.
We poured the reaction mixture onto ice
(100 g) and acidified the water layer with
3N HCI and extracted it three times with
dichloromethane. The organic layer was
washed with water, dried over MgSO4, and
the solvent was evaporated. The orange
residue was purified by column chromatog-
raphy (silica; CH2Cl2). Com-pound 10
was collected as a yellow powder (750 mg,
18%), melting point 250-251°C (dec).
Compound 10:lH-NMR: d 3.58 [t, 2H, i
5.6, H(7,7')]; 3.75 [t, 2H,J5.6, H(6,6 ')];
7.66 [d, J7.2, H(8)]; 7.82 [dd, J 8.2, 7.2,
H(2)]; 7.86 [dd,J8.1, 7.2, H(9)]; 8.08 [d,J
7.2, H(3)]; 8.35 [d,J8.1, H(10)]; 8.73 [d,J
8.2, H(1)]. UV (meth-anol) EXmax, nm;
(relative £)]: 252 (1.00), 280sh (0.70),
342sh (0.17), 380sh (0.07), MS (150°C):
258 (55), 230 (100), 202 (74), 201 (14),
200 (19), 113 (47).
4,5,6,7-Tetrahydrocyclopent[hi]ace-
phenanthrylene (11). Compound 10 (750
mg, 2.9 mmol) was reduced with hydra-zine
monohydrate (3.0 ml, 60 mmol) and KOH
(3.0 g) in diethylene glycol (80 ml) in the
same manner as described for the prepara-
tion ofcompound 9. Column chromatog-
raphy (silica; petroleum ether) and recrystal-
lization (cyclohexane) furnished compound
11 (430 mg. 64%) as white plates, melting
point 194-195°C. Compound 11: IH-
NMR: d 3.29 [m, 4H, H(4,4',7,7')]; 3.47
[m, 4H, H(5, 5',6,6')]; 7.43 [d, 2H, J7.1,
H(3,8)]; 7.53 [dd, 2H,J8.0, 7.1, H(2,9)];
8.23 [d, 2H, J 8.0, H(1,10)]. UV (cyclo-
hexane) [m., nm; (relative £)]: 254 (0.74),
262 (1.00), 284 (0.15), 296 (0.17), 309
(0.27), 327 (0.015), 343 (0.032), 361
(0.052). Exact mass calculated for C18H14:
230.1096 m/z found: 230.1093 m/z. MS
(75°C): 230 (100), 229 (50), 228 (21), 227
(20), 226 (19) 202 (10), 113 (18).
Cyclopent[hilacephenanthrylene. Com-
pound 11 (116 mg, 0.50 mmol) was dis-
solved in dry, freshly distilled toluene (40
ml) under an argon atmosphere, and DDQ
(273 mg, 1.15 mmol) was added under stir-
ring. We heated the solution to 80°C and
kept it at that temperature for 1 hr. The
solution was allowed to cool to room tem-
perature and was filtered over a short col-
umn of silica. Evaporation of the solvent
yielded CPAP as a light-orange solid.
Column chromatography (silica; CH2Cl2/
petroleum ether 1:9) and recrystallization
(cyclohexane) furnished CPAP as yellow
needles, melting point 162- 163°C (dec).
CPAP: 'H-NMR: d 7.29 [d, 2H, J 5.3,
H(5,6)]; 7.41 [d, 2H, J 5.3, H(4,7)]; 7.69
[dd, 2HJ7.6, 7.0 H(2,9)]; 7.73 [d, 2H, J
7.0 H(3,8)]; 8.38 [d, 2H J 7.6 H(1,10)].
13C NMR (CDCI3): d 122.0, 123.0, 126.0,
126.1q, 128.0, 130.7q, 135.5, 136.1q,
139.6q ppm. UV (cyclohexane) [max' nm;
(E, 1-molE cm- )]: 224 (27300), 266sh
(28500), 273 (34200), 326sh (11300), 338
(16600), 355 (20400), 374sh (6000), 393
(3800). Exact mass calculated for C18H,O:
226.0893 m/z found: 226.0782 m/z. MS
(25°C): 226 (100), 225 (12), 224 (15), 113
(31),1 12 (18).
Results and Discussion
Bacterial MutagenicityAssay
The four C18H,O isomers were tested in a
forward mutation assay based on S. typhi-
murium as described in Methods. Ad-
ditional details concerning this assay have
Volume 101, Number2, June 1993 149been published elsewhere (28,29). All iso-
mers were tested in the presence of an
exogenous metabolizing enzyme system
(PMS). Such enzyme mixtures are general-
ly required to obtain a mutagenic result for
PAHs with bacterial assays.
The results for two C18HHo isomers are
shown in Figure 3a and b, and these can be
compared with the result for benzo[a]-
pyrene (BaP) shown in Figure 3c. All
compounds were tested with identical
batches of bacteria and PMS to facilitate
comparison. The Y-scale range for MF
(0-80 x 10-5) is the same for the three in
Figure 2. Error bars reflect the 99% confi-
dence intervals for each determination.
As evidenced from this Figure 3, both
BF and CPP are roughly twice as muta-
genic as BaP. In all cases, toxicity is very
low at the dose levels tested, as indicated
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Figure 3. Bacterial mutagenicity results for two
C18H10 PAH isomers and a benzolalpyrene refer-
ence sample. Dose-response curves were
obtained from duplicate forward mutation assays
with S. typhimurium in the presence of an exoge-
nous metabolizing enzyme system. Mutagenicity
data (lower curves) are represented by filled
squares and are indexed to the left vertical scale;
the corresponding toxicity data (upper curves)
are represented by open squares and are in-
dexed to the right vertical scale. Error bars for
the mutagenicity data represent SDs. (a) Benzo-
[gh,lfluoranthene; (b) cyclopenta[cdlpyrene; (c)
benzo[a]pyrene.
Figure 4. Bacterial mutagenicity results for two dicyclopenta-fused C18H10 PAH isomers and their mono-
cyclopenta-fused analogs. Dose-response curves were obtained from duplicate forward mutation
assays with S. typhimurium in the presence of an exogenous metabolizing enzyme system. Mutagenicity
data (lower curves) are represented byfilled squares and are indexed to the leftvertical scale;the corre-
sponding toxicity data (upper curves) are represented by open squares and are indexed to the rightverti-
cal scale. Error bars forthe mutagenicity data represent SDs. (a) Cyclopentih/laceanthrylene; (b) acean-
thrylene; (c) cyclopent[hilacephenanthrylene; (d) acephenanthrylene.
by survival values near 100%. Mutagenic-
ity results for CPAP and CPAA are shown
in Figure 4. As illustrated in Figure 4a,
CPAA is the most potent bacterial muta-
gen ofthe four C18H0o isomers tested and
is approximately three times as mutagenic
as BaP in this assay. CPAP, although
yielding statistically significant mutagenici-
ty results, is relatively inactive compared
with BaP.
Bacterial mutagenicity results for
CPAA and CPAP were compared with
those of their monocyclopenta-fused
analogs, AA and AP. In Figure 4a and b,
results for CPAA are compared with those
for AA; in Figure 4c and 4d, results for
CPAP are compared with those for AP.
Although results for CPAP and AP were
similar, the mutagenic activity of CPAA
was an order of magnitude greater than
that of AA. When comparing results for
CPAA and AA, it should be noted that
horizontal scale (dose) values are roughly
an order of magnitude lower for CPAA
(0-5 gg/mL) than for AA (0-40 pg/ml).
CPAA is one of the most potent bacterial
mutagens tested to date in our forward
mutation assay.
Human Cell MutagenicityAssay
In addition to the bacterial assay, the com-
pounds were also tested for mutagenic
activity at the tk locus in MCL-3 cells.
Results for BF, CPP, and BaP are shown in
Figure 5a, b and c, respectively. For this
assay, error bars reflect 1 SD from the
mean value. Mutagenicity values on the
vertical axes are in units of 1 x 10-6 mutant
fraction or parts per million. As shown in
Figure 5, BaP is a very potent mutagen in
this assay, showing statistically significant
mutagenic activity below 0.5 pg/ml. CPP
is also an important human cell mutagen,
but it is less active than BaP in this assay.
In contrast, BF (Fig. 5a) is inactive in
this human cell assay but quite active in
bacteria as shown earlier (Fig. 3a). It
should be noted that the BF analogs fluo-
ranthene, benzo[b]fluoranthene, benzo-
j]fluoranthene, and benzo[k]fluoranthene
(each has an internal cyclopenta-fused ring)
are also inactive in the MCL-3 assay.
Fluoranthene, however, is active in our bac-
terial assay (22'). Presumably, the MCL-3
line ofhuman cells lacks the enzyme(s) nec-
essary for metabolic activation of fluoran-
thene-based PAHs.
Human cell mutagenicity results for
CPAA and CPAP were compared with
those of their monocyclopenta-fused ana-
logs AA and AP. Results for CPAA com-
pared with those of AA are shown in
Figure 6a and b, respectively, and results
for CPAP compared with those ofAP are
shown in Figure 6c and d, respectively.
Comparing the results for CPAP and AP,
it is seen that both PAHs are negative in
this assay. On the other hand, both
CPAA and AA are mutagenic. When
comparing results for CPAA and AA, it
should be noted that the horizontal scale
(dose) is a factor of 10 smaller for CPAA
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(0.0-0.9 pg/ml) than for AA (0-9 pg/ml).
Comparing the data in Figure 6a and b, it
is seen that the human cell mutagenicity
ofCPAA is more than an order ofmagni-
tude greater than that ofAA.
Considering both the bacterial and
human cell data, it can be hypothesized
that the addition of peripherally fused
cyclopenta groups to anthracene-based
molecules will have a significant biological
effect, but the addition ofthe same groups
to phenanthrene-based structures will have
little effect. No adequate explanation of
the differences in the mutagenicity ofthese
cyclopenta-fused PAHs can be offered
until more information becomes available
on the metabolism of these unique com-
pounds.
Chemical Identification
Identification ofC18H1o PAH isomers in
complex mixtures is hampered by a num-
ber of technical difficulties; however, the
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Figure 5. Human cell mutagenicity results for
C18H1polycyclic aromatic hydrocarbons and a
benzo alpyrene reference sample. Mutagenicity
data (lower curves) from duplicate experiments
are represented by filled squares and are in-
dexed to the left vertical scale; the correspond-
ing toxicity data (upper curves) are represented
by open squares and are indexed to the right ver-
tical scale. Error bars for the mutagenicity data
represent SDs. (a) Benzo[gh,lfluoranthene; (b)
cyclopenta[cdlpyrene; (c) benzo[a]pyrene.
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Figure 6. Human cell mutagenicity results for two dicyclopenta-fused C18H1o PAH isomers and their
monocyclopenta-fused analogs. Mutagenicity data (lower curves) are represented by filled squares and
are indexed to the left vertical scale; the corresponding toxicity data (upper curves) are represented by
open squares and are indexed to the right vertical scale. Error bars for the mutagenicity data represent
the SDs. (a) Cyclopentihilaceanthrylene; (b) aceanthrylene; (c) cyclopent[hilacephenanthrylene; (d)
acephenanthrylene.
lack of reference standards has been the
major obstacle. In this study, the availabil-
ity of four C18Ho isomers has enabled us
to identify unequivocally the major
C18HIo species emitted from a range of
combustors and also has allowed us to shed
some light on the effectiveness of selected
analytical techniques for the analysis of
these species in complex mixtures.
GC/MS is currently the method of
choice for the separation and identification
of PAHs (24); however, even GC/MS suf-
fers from some important drawbacks when
used for the analysis of complex mixtures
for C18H1o PAHs. For example, the simi-
larity of mass spectra of PAHs having the
same molecular composition prevents the
differentiation of isomers, while at the
same time, it is often difficult to complete-
ly resolve C18H1o isomers from interfering
species. In addition, coeluting C18Hl2
PAHs can mask contributions from less
abundant C18H1o PAHs because the for-
mer give m/z 226 fragment ions, which
can be mistaken for C18H1o molecular
ions.
The introduction of diode array spec-
tral data acquisition in HPLC (HPLC/
DAD) has provided the potential to differ-
entiate PAH isomers because PAHs gener-
ally give highly characteristic UV spectra,
even for isomers. However, even with
HPLC/DAD, the analysis ofcomplex mix-
tures for C18H1o PAHs was found to give
some difficulties: Even under currently
optimal HPLC conditions, CPP and BF
generally coelute, and unfortunately, have
similar UV spectra. Moreover, it was
found that the UV spectra of CPP, BF,
CPAA, and CPAP could be masked be-
yond recognition by contributions from
other coeluting PAHs (e.g., C18H12 iso-
mers andalkyl-C16H1O PAHs).
Through the combined use of HPLC/
DAD and GC/MS and by the use of the
C18H1o reference standards, unequivocal
identification of CPP, CPAP, and BF was
made for a number of combustion sam-
ples. Comprehensive chemical analysis
results for a range of combustors and
pyrolyzers will be presented elsewhere;
however, our present work focuses on the
identification ofC18H1o isomers in com-
bustion products from a jet-stirred/plug-
flow reactor, a research combustor that
gives results typical of a number of practi-
cal combustion systems.
The jet-stirred/plug-flow reactor was
designed to provide well-defined combus-
tion conditions, and its use is part of an
ongoing program aimed at understanding
and controlling the combustion chemistry
responsible for mutagen formation. De-
tailed descriptions of this combustor are
available elsewhere (23-25).
Figure 7 shows a portion ofan HPLC/
DAD total-absorbance chromatogram
obtained for an ethylene combustion sam-
ple from the combustor. Conditions are
given in the Methods. The wide-band
absorbance (236-500 nm) in absorbance
units is plotted against the elution volume
in milliliters. For PAHs, the wide-band
absorbance is roughly proportional to mass
(27). In Figure 7, the major peak, centered
at 25 ml, was identified as CPP from the
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Figure 7. Total absorbance chromatograms obtained over the 236-500 nm wavelength interval showing
the presence of C18H10 isomers cyclopenta[cdapyrene and cyclopentlh/lacephenanthrylene in a sample
produced from the combustion of ethylene in a jet-stirred/plug-flow reactor. See Methods for details.
Other PAHs identified in the samples include acephenanthrylene, fluoranthene, and pyrene.
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Figure 8. Mass chromatogram of m/e 226 (C18H10) for an ethylene combustion sample taken from a jet-
stirred/plug-flow combustor. Three C18H10 isomers are identified: cyclopentalcdlpyrene, benzo[gh,lfluo-
ranthene, and cyclopent[hilacephenanthrylene. A number of other C18H10 isomers, identified through
their mass spectra, are indicated by peaks a- h.
HPLC/DAD data; however, further analy-
sis by GC/MS showed that the major peak
also contained BF. Quantitative analysis by
GC/flame ionization detection gave a value
of 16% for BF. The other C18H1o PAHs
identified in this sample was CPAP, which
was completely resolved from the CPP +
BF peak. The earlier-eluting peaks anno-
tated in Figure 7 are those ofAP, fluoran-
thene, and pyrene.
Because our combustion conditions do
not promote the formation of C18Hl2
PAHs (e.g., chrysene, benz[a]anthracene)
or other interfering species, the HPLC
chromatogram appears quite simple. How-
ever, when an HPLC fraction containing
C18H1o PAH isomers was collected and
analyzed by GC/MS, the additional resolu-
tion provided by a capillary GC column
revealed a more complex picture.
Figure 8 shows the C18H1o mass chro-
matogram (m/e 226) for another ethylene
combustion sample taken from our jet-
stirred/plug flow combustor. The three
C18HIo isomers (CPP, BF, CPAP) that
were incompletely resolved by HPLC (Fig.
7) are better resolved by capillary gas chro-
matography. Moreover, at increased reso-
lution, the presence ofadditional isomers is
revealed. A number of other C18H1o iso-
mers, identified through their mass spectra,
were also found in the sample. They are
indicated by peaks a-h in Figure 8. One of
these additional isomers is likely to be
cyclopenta[ca fluoranthene. Other C18Hlo
PAHs can be formed in the combustor
through the addition ofan acetylene group
to a C16H10 PAH (e.g., fluoranthene,
pyrene). Evidence for the possible existence
of these types of structures is provided by
the presence in the sample ofphenyl acety-
lene, 2-ethynyl naphthalene, and a number
ofethynyl acenaphthylenes (4,5).
Also seen in Figure 8 are some other
components eluting close to the C18H0o
PAHs, and they are labeled with their mol-
ecular ion values obtained from their mass
spectra. The small peak labeled 228 is a
C18H12 isomer; the one labeled 240 gave a
mass spectrum consistent with a C18H12
species incorporating an added methylene
bridge. The 214 peak is thought to be a
methylene-bridged acephenanthrylene.
Summary
In a forward mutation assay using on S.
typhimurium, CPP, BF, and CPAA were
roughly twice as potent as BaP, whereas
CPAP was onlyslightly active. In a human
cell mutagenicity assay usinF MCL-3 cells,
a derivative ofAHH-1 TK+ cells contain-
ing higher native P450 lAl activity, CPP
and CPAA were strongly mutagenic but
less active than BaP, while CPAP and BF
were inactive at the dose levels tested.
Bacterial and human cell mutagenicity
results for CPAA and CPAP were com-
pared with those oftheir monocyclopenta-
fused analogs AA and acephenanthrylene
AP. Mutagenicity results for both human
cells and bacteria showed that the muta-
genic activity of CPAP generally approxi-
mated that of AP: Both were inactive in
human cells and weakly mutagenic in bac-
teria. In contrast, the mutagenic activity of
CPAA was roughly an order ofmagnitude
greater than that of AA in both assays.
Results of chemical analyses showed that
C18H1o CP-PAHs were abundant in every
combustion and pyrolysis sample tested.
Generally, CPP was the most abundant
and the most frequently occurring C18HHo
isomer, whereas CPAP was equally com-
mon but present but at lower levels. BF
was also found in a number of samples,
whereas CPAAwas undetected.
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